BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30367145)

  • 1. Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model.
    Jin Y; Wei L; Jiang Q; Song X; Teng C; Fan C; Lv Y; Liu Y; Shen W; Li L; Huang D; Xin T
    Sci Rep; 2018 Oct; 8(1):15837. PubMed ID: 30367145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer-bearing mice and patients.
    Liu M; Li H; Wang X; Jing L; Jiang P; Li Y
    Cancer Med; 2020 Apr; 9(8):2660-2673. PubMed ID: 32073228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy.
    Zhou S; Zuo L; He X; Pi J; Jin J; Shi Y
    Thorac Cancer; 2018 Nov; 9(11):1354-1360. PubMed ID: 30152052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of apatinib combined with chemotherapy or targeted therapy on non-small cell lung cancer in vitro and vivo.
    Liu M; Wang X; Li H; Xu L; Jing L; Jiang P; Liu B; Li Y
    Thorac Cancer; 2019 Oct; 10(10):1868-1878. PubMed ID: 31486270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human endostatin, Endostar, enhances the effects of chemo-radiotherapy in a mouse cervical cancer xenograft model.
    Jia Y; Liu M; Cao L; Zhao X; Wu J; Lu F; Li Y; He Y; Ren S; Ju Y; Wang Y; Li Z
    Eur J Gynaecol Oncol; 2011; 32(3):316-24. PubMed ID: 21797125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.
    Han B; Xiu Q; Wang H; Shen J; Gu A; Luo Y; Bai C; Guo S; Liu W; Zhuang Z; Zhang Y; Zhao Y; Jiang L; Zhou J; Jin X
    J Thorac Oncol; 2011 Jun; 6(6):1104-9. PubMed ID: 21532504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience.
    Greillier L; Tomasini P; Barlesi F
    Ther Adv Respir Dis; 2016 Oct; 10(5):485-91. PubMed ID: 27340254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematical comparison of anti-angiogenesis and anti-cancer efficacy of ramucirumab, apatinib, regorafenib and cabozantinib in zebrafish model.
    Wu JQ; Fan RY; Zhang SR; Li CY; Shen LZ; Wei P; He ZH; He MF
    Life Sci; 2020 Apr; 247():117402. PubMed ID: 32035930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non-small Cell Lung Cancer Xenograft Models.
    Ishikura N; Yanagisawa M; Noguchi-Sasaki M; Iwai T; Yorozu K; Kurasawa M; Sugimoto M; Yamamoto K
    Anticancer Res; 2017 Feb; 37(2):623-629. PubMed ID: 28179309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study on the efficacy of recombinant human endostatin combined with apatinib mesylate in patients with middle and advanced stage non-small cell lung cancer.
    Zhao J; Yu H; Han T; Wang W; Tong W; Zhu X
    J BUON; 2019; 24(6):2267-2272. PubMed ID: 31983093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrasound-targeted microbubble destruction improved the antiangiogenic effect of Endostar in triple-negative breast carcinoma xenografts.
    Jing Y; Xiu-Juan Z; Hong-Jiao C; Zhi-Kui C; Qing-Fu Q; En-Sheng X; Li-Wu L
    J Cancer Res Clin Oncol; 2019 May; 145(5):1191-1200. PubMed ID: 30805775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts.
    Rolff J; Becker M; Merk J; Hoffmann J; Fichtner I
    Target Oncol; 2016 Aug; 11(4):507-14. PubMed ID: 26817645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab combined with apatinib enhances antitumor and anti-angiogenesis effects in a lung cancer model
    Wang M; Zeng Q; Li Y; Imani S; Xie D; Li Y; Han Y; Fan J
    J Drug Target; 2020 Nov; 28(9):961-969. PubMed ID: 32374627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inhibitory effects of rh-endostatin (YH-16) in combination with radiotherapy on lung adenocarcinoma A549 in mice and the underlying mechanisms.
    Wu H; Deng J; Yu S; Wang X; Chen Y
    J Huazhong Univ Sci Technolog Med Sci; 2010 Feb; 30(1):108-12. PubMed ID: 20155466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of icotinib combined with antiangiogenic drugs in human non-small cell lung cancer xenograft models are better than single target drugs.
    Jiang P; Zhang Y; Cui J; Wang X; Li Y
    Thorac Cancer; 2022 Jan; 13(2):257-264. PubMed ID: 34855286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC.
    Wu D; Liang L; Nie L; Nie J; Dai L; Hu W; Zhang J; Chen X; Han J; Ma X; Tian G; Han S; Long J; Wang Y; Zhang Z; Xin T; Fang J
    Asia Pac J Clin Oncol; 2018 Dec; 14(6):446-452. PubMed ID: 29573236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDGFR-β inhibitor slows tumor growth but increases metastasis in combined radiotherapy and Endostar therapy.
    Yin L; He J; Xue J; Na F; Tong R; Wang J; Gao H; Tang F; Mo X; Deng L; Lu Y
    Biomed Pharmacother; 2018 Mar; 99():615-621. PubMed ID: 29653486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy.
    Liu Z; Ou W; Li N; Wang SY
    Thorac Cancer; 2018 Oct; 9(10):1285-1290. PubMed ID: 30126078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current progression of bevacizumab in advanced non-small cell lung cancer].
    Chu TQ; Chen JH; Han BH
    Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):793-800. PubMed ID: 30392346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.